Navigation Links
ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Date:8/29/2007

SAN DIEGO, Aug. 29 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that Evan M. Levine, ADVENTRX's chief executive officer, is scheduled to present at the 2007 Thomas Weisel Partners Healthcare Conference on Wednesday, September 5th, 2007 at 1:30 p.m. Eastern Daylight Time. The conference takes place in Boston at the Four Seasons Hotel, September 5 - 7, 2007.

The presentation will be webcast live via the "Investors" section of the Company's web site at http://www.adventrx.com under "Events." The webcast will be available for replay for 14 days and can be accessed through the same link.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ mate
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...YNBROOK, N.Y., Nov. 5 Bi...biopharmaceutical company developing first-in-clas...financial results for the third quarter ended Sept...at, in September of this year, the FDA,s Arthritis...vote of 12-0, the approval of XIAFLEX(TM) for the ...
(Date:11/5/2009)...AN DIEGO, CA, November 5, 2009 /PRNewswire-FirstCa...ocused on using proprietary taste receptor-based t...or the food, beverage, and ingredient supply indus...ted financial results for the third quarter ended ...r the third quarter of 2009, compared to $4.0 mill...
(Date:11/5/2009)... PLYMOUTH MEETING, Pa., Nov. 5 /PRNewswire-Asia-...JGP ) ("BMP Sunstone" or the "Company") today anno...ter 2009 financial results on,Monday, November 9, ...any will hold a conference call at 5:00 pm ET on N...lts. Listeners may access the call by,dialing 1-8...
(Date:11/5/2009)... Brooke Sanders brings a new loo...CA (PRWEB) November 5, 2009 -- Professional Reprog...rographics company is pleased to present Brooke Sa...their graphics/PR specialist. The addition of Broo...ent growth within Professional Reprographics., , ,...
Breaking Biology Technology:BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14BMP Sunstone to Report Third Quarter 2009 Financial Results 2
...ERUSALEM, October 24 IDenta Corp. (Other,OTC: IDT...n report,regarding the penetration of the United S...nership between Jant Pharmacal Corporation (Encino...d in increasing market,penetration over the 2nd an...ave increased significantly in the United States w...
...ull Body Radiosurgery Expands Treatment Options fo...ver and Pancreatic Cancer, SUNNYVALE, Calif., Oct...bal leader in the field of radiosurgery,announced ... the,CyberKnife(R) Robotic Radiosurgery System inc...ear ending June 30, 2008. Specifically, during thi...
...EATTLE, Oct. 24 /PRNewswire-FirstCall/ - Oncothyre...company specializing in the development of,innovat...er, today,announced that Robert Kirkman, M.D., Pre... present at the 7th Annual BIO Investor Forum in S....m. Pacific Time., A live and archived webcast of...
Other Biology Technology:International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 2International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 4CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008 2CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008 3CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008 4
(Date:11/6/2009)...sary this month of the publication of On the Origi... Sciences (AIBS) is publishing open access two pee...istoric insights into evolution. , The two articl...rnia, Berkeley, and James T. Costa of Western Caro...t Charles Darwin," appeared in the October issue o...
(Date:11/6/2009)...9) The Monell Center and the Chinese Academy of S...ional Meeting on Taste and Smell Research. Organiz...eting will be the first international meeting on t...er, Chief Executive Officer, American Association ...sher of Science magazine, will open the meeting wi...
(Date:11/5/2009)... awarded a training grant in the amount of $2,756,...ntegrative Graduation Education and Research Train... to be awarded to Kent State. The grant, which is ...t Act of 2009, runs through 2014. , The grant fu...quatic resource sensing (EARS). The purpose of the...
Breaking Biology News(10 mins):Monell Center joins with CAS to host Beijing meeting on taste and smell research 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control 28APIC 29 Annual Conference 47882 1Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control 28APIC 29 Annual Conference 47882 2Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control 28APIC 29 Annual Conference 47882 3DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares 47877 1DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares 47877 2DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares 47877 3DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares 47877 4EUCODIS Bioscience Launches Beta Lactamase for Antibiotics and Diagnostics Industries 12462 1EUCODIS Bioscience Launches Beta Lactamase for Antibiotics and Diagnostics Industries 12462 2
...e world’s largest and least studied freshwater tur...ising hopes that the threatened species can be sav... International (CI), World Wildlife Fund (WWF), th...odian Turtle Conservation Team captured and relea...ant softshell turtle (Pelochelys cantorii) during ...
...fish virus in the Great Lakes and neighboring wate...ng to Paul Bowser, Cornell professor of aquatic an...e. The viral hemorrhagic septicemia virus (VHSV), ...now been identified in 19 species and poses a pote...ing industry. , "It’s pretty obvious this is an ep...
...sterone levels of healthy men decline as they get ...crease with age, objectively measured differences ...n affect his level of testosterone in the morning,...ssue of the journal SLEEP. , The study, conducted ...cago, focused on 12 healthy men between the ages o...
Other Biology News:Rare soft-shell turtle, nesting ground found in Cambodia 2Rare soft-shell turtle, nesting ground found in Cambodia 3Cornell lab confirms deadly fish virus spreading to new species 2
Mouse Anti-Human TNPO2 Polyclonal Antibody, Unconjugated from Novus Biologicals
... ChIP Grade HDAC4 is a member of the class II mam...4 amino acid residues. Its C-terminal sequence is ...HDA1. HDAC4, unlike other deacetylases, shuttles b...lving active nuclear export. Association of HDAC4 ...
FluoroGuard Antifade Reagent from Bio-Rad
Mouse Anti-Human PDK2 Monoclonal Antibody, Unconjugated, Clone 2G1 from Novus Biologicals
Biology Products: